Tehran University of Medical Sciences

Science Communicator Platform

Stay connected! Follow us on X network (Twitter):
Share this content! On (X network) By
Unraveling the Impact of 27-Hydroxycholesterol in Autoimmune Diseases: Exploring Promising Therapeutic Approaches Publisher Pubmed



Hjazi A1 ; Ahsan M2 ; Alghamdi MI3 ; Kareem AK4 ; Alsaidi DN5 ; Qasim MT6 ; Romeroparra RM7 ; Zabibah RS8 ; Ramirezcoronel AA9, 10, 11, 12 ; Mustafa YF13 ; Hosseinifard SR14 ; Karampoor S15 ; Mirzaei R16
Authors
Show Affiliations
Authors Affiliations
  1. 1. Department of Medical Laboratory Sciences, College of Applied Medical Sciences, Prince Sattam bin Abdulaziz University, Al-Kharj, 11942, Saudi Arabia
  2. 2. King Edward Medical University Lahore, Pakistan
  3. 3. Department of Computer Science, Al-Baha University, Al-Baha City, Saudi Arabia
  4. 4. Biomedical Engineering Department, Al-Mustaqbal University College, Babylon, Iraq
  5. 5. Department of Medical Laboratories Technology, AL-Nisour University College, Baghdad, Iraq
  6. 6. Department of Anesthesia, College of Health and Medical Technology, Al-Ayen University, Thi-Qar, Iraq
  7. 7. Department of General Studies, Universidad Continental, Lima, Peru
  8. 8. Medical Laboratory Technology Department, College of Medical Technology, The Islamic University, Najaf, Iraq
  9. 9. Health and Behavior Research Group (HBR), Psychometry and Ethology Laboratory, Catholic University of Cuenca, Ecuador
  10. 10. University of Palermo, Buenos Aires, Argentina
  11. 11. Research group in educational statistics, National University of Education, Azogues, Ecuador
  12. 12. Epidemiology and Biostatistics Research Group, CES University, Colombia
  13. 13. Department of Pharmaceutical Chemistry, College of Pharmacy, University of Mosul, Mosul, 41001, Iraq
  14. 14. Department of Biochemistry, School of Medicine, Tehran University of Medical Sciences, Tehran, Iran
  15. 15. Gastrointestinal and Liver Diseases Research Center, Iran University of Medical Sciences, Tehran, Iran
  16. 16. Venom and Biotherapeutics Molecules Lab, Medical Biotechnology Department, Biotechnology Research Center, Pasteur Institute of Iran, Tehran, Iran

Source: Pathology Research and Practice Published:2023


Abstract

The role of 27-hydroxycholesterol (27-OHC) in autoimmune diseases has become a subject of intense research in recent years. This oxysterol, derived from cholesterol, has been identified as a significant player in modulating immune responses and inflammation. Its involvement in autoimmune pathogenesis has drawn attention to its potential as a therapeutic target for managing autoimmune disorders effectively. 27-OHC, an oxysterol derived from cholesterol, has emerged as a key player in modulating immune responses and inflammatory processes. It exerts its effects through various mechanisms, including activation of nuclear receptors, interaction with immune cells, and modulation of neuroinflammation. Additionally, 27-OHC has been implicated in the dysregulation of lipid metabolism, neurotoxicity, and blood-brain barrier (BBB) disruption. Understanding the intricate interplay between 27-OHC and autoimmune diseases, particularly neurodegenerative disorders, holds promise for developing targeted therapeutic strategies. Additionally, emerging evidence suggests that 27-OHC may interact with specific receptors and transcription factors, thus influencing gene expression and cellular processes in autoimmune disorders. Understanding the intricate mechanisms by which 27-OHC influences immune dysregulation and tissue damage in autoimmune diseases is crucial for developing targeted therapeutic interventions. Further investigations into the molecular pathways and signaling networks involving 27-OHC are warranted to unravel its full potential as a therapeutic target in autoimmune diseases, thereby offering new avenues for disease intervention and management. © 2023 Elsevier GmbH
Related Docs
View other Related Docs
1. The Beneficial Effects of Hmg-Coa Reductase Inhibitors in the Processes of Neurodegeneration, Metabolic Brain Disease (2017)
2. Multiple Sclerosis: Clinical Features, Pathophysiology, Diagnosis, and Management, Neuroinflammation (2018)
3. A Comprehensive Review on the Treatment Approaches of Multiple Sclerosis: Currently and in the Future, Inflammation Research (2019)
4. Consensus Recommendations for the Diagnosis and Treatment of Multiple Sclerosis: 2019 Revisions to the Menactrims Guidelines, Multiple Sclerosis and Related Disorders (2020)
5. Consensus Recommendations for the Diagnosis and Treatment of Multiple Sclerosis: The Middle East North Africa Committee for Treatment and Research in Multiple Sclerosis (Menactrims), Current Medical Research and Opinion (2015)
6. Intervening to Reduce the Risk of Future Disability From Multiple Sclerosis: Are We There Yet?, International Journal of Neuroscience (2017)
7. Consensus Recommendations for Diagnosis and Treatment of Multiple Sclerosis: 2023 Revision of the Menactrims Guidelines, Multiple Sclerosis and Related Disorders (2024)
8. Current Insights Into Pathogenesis of Parkinson's Disease: Approach to Mevalonate Pathway and Protective Role of Statins, Biomedicine and Pharmacotherapy (2017)
Experts (# of related papers)
View all Related Experts
Mohammad Ali Sahraian (7)
Nima Rezaei (5)
Other Related Docs
9. The Pathogenic, Therapeutic and Diagnostic Role of Exosomal Microrna in the Autoimmune Diseases, Journal of Neuroimmunology (2021)
10. The Skewed Balance Between Tregs and Th17 in Chronic Lymphocytic Leukemia, Future Oncology (2015)
11. Emerging Epidemic of Inflammatory Bowel Disease in a Middle Income Country: A Nation-Wide Study From Iran, Archives of Iranian Medicine (2016)
12. Immune Reconstitution Therapy or Continuous Immunosuppression for the Management of Active Relapsing–Remitting Multiple Sclerosis Patients? a Narrative Review, Neurology and Therapy (2020)
13. Targeting Pathophysiological Changes Using Biomaterials-Based Drug Delivery Systems: A Key to Managing Inflammatory Bowel Disease, Frontiers in Pharmacology (2022)
14. Efficacy of Disease Modifying Therapies in Progressive Ms and How Immune Senescence May Explain Their Failure, Frontiers in Neurology (2022)
15. Systematic Review and Meta-Analysis of the Incidence and Prevalence and 30-Year Trend of Inflammatory Bowel Diseases in Asia: A Study Protocol, BMJ Open (2019)
16. Cancer Immunology, Encyclopedia of Infection and Immunity (2022)
17. Pharmacokinetics and Bioequivalence Studies of Teriflunomide in Healthy Iranian Volunteers, Clinical Pharmacology in Drug Development (2020)
18. Cost-Effectiveness of Alemtuzumab and Natalizumab for Relapsing-Remitting Multiple Sclerosis Treatment in Iran: Decision Analysis Based on an Indirect Comparison, Journal of Medical Economics (2019)
19. The Efficacy and Safety of Oral Disease-Modifying Therapies for Relapsing-Remitting Multiple Sclerosis: A Systematic Review, Current Journal of Neurology (2020)
20. Alzheimer's Disease in Diabetic Patients: A Lipidomic Prospect, Neuroscience (2023)
21. Autoimmune Diseases, Clinical Immunology (2022)
22. The Pro-Tumorigenic Responses in Metastatic Niches: An Immunological Perspective, Clinical and Translational Oncology (2023)
23. A Mechanistic Review on Plant-Derived Natural Compounds As Dietary Supplements for Prevention of Inflammatory Bowel Disease, Expert Review of Gastroenterology and Hepatology (2016)
24. Monoclonal Antibodies in Multiple Sclerosis Treatment, Translational Neuroimmunology: Multiple Sclerosis: Volume 8 (2023)
25. Comparable Efficacy and Safety of Teriflunomide Versus Dimethyl Fumarate for the Treatment of Relapsing-Remitting Multiple Sclerosis, Neurology Research International (2021)